richard veyrat-masson MD Hematology
Course and current status
I earned a degree of M.D. in 2006. Since 2002, I worked on Mesenchymal Stem Cells and published a phenotype and culture quality control for therapeutics used in 2007. I have been appointed as physician in charge of clinical laboratories for characterization and diagnosis of haematological malignancies by flow cytometry in 2004. In 2009, I joined the EA3846 team and then started study chronic lymphocytic leukaemia (CLL). In an in vitro model, I study CLL cell signalling involved in chemoresistance.
Scientific summary
Chronic lymphocytic leukaemia (CLL) remains an incurable disease with most patients developing resistance to therapy. In vitro, CLL cells rapidly enter in apoptosis. Since 2009 I have developed an in vitro culture model allowing a better survive for 4 to 6 days. In this model I study signalling pathways (essentially NFkappaB) implicated in Fludarabine chemoresistance (gold standard treatment).
